麻豆国产精品一二三在线观-麻豆国产精品一二三在线观看-麻豆国产精品一区二区-麻豆国产精品永久免费视频-麻豆国产巨作av剧情-麻豆国产蜜桃臀视频在线观看

美國(guó)KaloBios Pharmaceuticals
Humaneering（TM）是KaloBios制藥的專利治療方法，用于將非人體抗體轉(zhuǎn)為應(yīng)用于治療藥物的工程人體抗體。該系統(tǒng)具有保持抗原決定基特異性和提高親和性的優(yōu)點(diǎn)。KaloBios正在有限的基礎(chǔ)上提供利用humaneering（TM）功能的機(jī)會(huì)。

KaloBios Pharmaceuticals, Inc., a U.S. based, private monoclonal company, uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. The company has multiple programs that were in seven Phase 1 or 2 clinical trials in 2008/09: KB001 is an anti-infective for Pseudomonas aeruginosa infections being tested in cystic fibrosis and in intensive care patients on a ventilator, and KB002 and KB003 are being evaluated in inflammatory conditions, such as rheumatoid arthritis and asthma. KB004 is in preclinical development for oncology, and the company plans to file an IND for it in 1H 2010. The company抯 Humaneering?technology offers advantages over other methods of human antibody creation in terms of immunogenicity, potency, and manufacturing yields. The company is focusing on partnering its clinical-stage programs in 2009 and may grant limited access to its Humaneering?technology platform to select partners.

KaloBios was formed in 2001 and merged in 2004 with Celscia. Since the company抯 founding, it has raised a total of $80 million in four rounds of venture funding with the major shareholders being MPM Capital, Sofinnova Ventures, Alloy Ventures, GBS Venture Partners, Mitsubishi UFJ Capital, Genzyme Ventures, Baxter International, Inc., and the Development Bank of Japan. The company is headquartered in South San Francisco, CA and has approximately 50 employees.

?

Mission
Our mission is to become a leading biopharmaceutical company developing and commercializing biotherapies to treat unmet medical needs. We are committed to working to high standards of excellence and integrity to bring improved treatment options to patients, rewarding employment to our employees and significant returns to our stockholders.
?